Abstract
Platelets possess two receptors for ADP, P2Y1 and P2Y12. ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y1 receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation. The P2Y12 receptor on the other hand is linked to Gi and plays a special role in the amplification of platelet activation initiated by numerous other pathways. Platelet activation leads to a range of responses that play a critical role in arterial thrombosis and the inflammatory responses associated with this, including platelet aggregation, dense and α granule secretion and procoagulant activity. P2Y12 receptor activation yields powerful amplification of these processes such that P2Y12 receptor antagonists may have dramatic inhibitory effects on platelet function regardless of the activating stimuli. This phenomenon, coupled with the restricted distribution of the P2Y12 receptor in humans, makes the receptor an ideal target for pharmaceutical therapy. This has already been established by the therapeutic success of clopidogrel, which acts, via an active metabolite, on this receptor. However, current therapeutic regimens of clopidogrel yield variable and incomplete P2Y12 receptor blockade and more effective strategies to block P2Y12 receptor activation offer the potential of greater clinical efficacy.
Keywords: receptor-operated cation channel, antiplatelet effects, ATP, clopidogrel, Platelet activation
Current Pharmaceutical Design
Title: Biology and Pharmacology of the Platelet P2Y12 Receptor
Volume: 12 Issue: 10
Author(s): Robert F. Storey
Affiliation:
Keywords: receptor-operated cation channel, antiplatelet effects, ATP, clopidogrel, Platelet activation
Abstract: Platelets possess two receptors for ADP, P2Y1 and P2Y12. ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y1 receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation. The P2Y12 receptor on the other hand is linked to Gi and plays a special role in the amplification of platelet activation initiated by numerous other pathways. Platelet activation leads to a range of responses that play a critical role in arterial thrombosis and the inflammatory responses associated with this, including platelet aggregation, dense and α granule secretion and procoagulant activity. P2Y12 receptor activation yields powerful amplification of these processes such that P2Y12 receptor antagonists may have dramatic inhibitory effects on platelet function regardless of the activating stimuli. This phenomenon, coupled with the restricted distribution of the P2Y12 receptor in humans, makes the receptor an ideal target for pharmaceutical therapy. This has already been established by the therapeutic success of clopidogrel, which acts, via an active metabolite, on this receptor. However, current therapeutic regimens of clopidogrel yield variable and incomplete P2Y12 receptor blockade and more effective strategies to block P2Y12 receptor activation offer the potential of greater clinical efficacy.
Export Options
About this article
Cite this article as:
Storey F. Robert, Biology and Pharmacology of the Platelet P2Y12 Receptor, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361318
DOI https://dx.doi.org/10.2174/138161206776361318 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science Impact of Oral 1,25-Dihydroxy Vitamin D (Calcitriol) Replacement Therapy on Coronary Artery Risk Factors in Type 2 Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Endothelial Lipase: A Key Player in HDL Metabolism Modulates Inflammation and Atherosclerotic Risk
Mini-Reviews in Medicinal Chemistry Design, Synthesis, and Biological Evaluation of Novel Tetramethylpyrazine- nitrone Derivatives as Antioxidants
Letters in Drug Design & Discovery Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypertension in Pregnancy: A Review of Current Guidelines
Current Women`s Health Reviews Targeting Platelet G-Protein Coupled Receptors (GPCRs): Looking Beyond Conventional GPCR Antagonism
Current Vascular Pharmacology Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Age Related Macular Degeneration and Visual Disability
Current Drug Targets Computational and Pathway Analysis of nsSNPs of MED23 Gene Involved in Human Congenital Diseases
Current Biotechnology Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis
Current Pharmacogenomics and Personalized Medicine 58-Year Old Men with Non-Stenotic Carotid Artery Plaques and the Relationship with Cardiovascular Risk Factors and Future Cardiovascular Events
Vascular Disease Prevention (Discontinued) Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease
Current Protein & Peptide Science Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy
Current Gene Therapy Soluble (Pro) Renin Receptor is a Predictor of Gestational Diabetes Mellitus
Current Diabetes Reviews Dyslipidemia as a Risk Factor for Ischemic Stroke
Current Topics in Medicinal Chemistry Recent Clinical Aspects of Eating Disorders
Reviews on Recent Clinical Trials Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Receptor Fragments: Intracellular Signaling and Novel Therapeutic Targets
Current Hypertension Reviews Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine